DexCom price target raised to $44 from $34 at Canaccord Canaccord said DexCom's preliminary Q4 results were strong and demonstrate the market-expanding potential for the next-gen Gen4 Platinum sensor. Shares are Buy rated.
News For DXCM From The Last 14 Days
Check below for free stories on DXCM the last two weeks.
DexCom upgraded at Sterne Agee As noted earlier, Sterne Agee upgraded DexCom to Buy from Neutral. The firm expects the company to generate strong annual revenue growth, and believes that use of its G4 Platinum product will become more widespread after the FDA approved it for people ages 2-17. Target $50.